Covaxin

Covaxin, technically designated BBV152, is India's first wholly indigenous vaccine against SARS-CoV-2, developed by the Hyderabad-based Bharat Biotech International Limited in partnership with the Indian Council of Medical Research (ICMR) and its National Institute of Virology (NIV), Pune. It was developed under the public–private "Mission COVID Suraksha" framework supported by the Department of Biotechnology and Biotechnology Industry Research Assistance Council (BIRAC). The vaccine candidate was built around a virus strain isolated by the NIV, making it a flagship example of the Atmanirbhar Bharat (self-reliant India) initiative in the health-technology sector. India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), granted it restricted emergency-use authorisation on 3 January 2021, alongside the Serum Institute's Covishield.

Covaxin is a whole-virion inactivated vaccine — it uses the killed (non-replicating) SARS-CoV-2 virus, grown in Vero cell lines and inactivated using beta-propiolactone, so it cannot cause infection but still presents multiple viral antigens to the immune system. It is adjuvanted with Algel-IMDG, an imidazoquinoline-class TLR7/8 agonist adsorbed to alum, which boosts the immune response. This is the same classical platform used for established vaccines against rabies, polio (Salk), and hepatitis A, distinguishing it from the viral-vector (Covishield/AstraZeneca) and mRNA (Pfizer, Moderna) platforms. It is administered in a two-dose intramuscular schedule and is stored at standard 2–8°C refrigeration, an advantage for India's cold chain. Its Phase 3 trial reported an interim efficacy of about 77.8% against symptomatic disease.

A central controversy concerned the sequencing of approval before Phase 3 efficacy data were published, which drew criticism over transparency and the "clinical trial mode" rollout. Covaxin received WHO Emergency Use Listing (EUL) on 3 November 2021, which was significant for vaccine diplomacy and recognition of Indian-vaccinated travellers abroad. India deployed Covaxin extensively under its national immunisation drive and exported it under the Vaccine Maitri programme. By 2026 it remains a benchmark case in India's pharmaceutical sovereignty narrative, frequently cited alongside the country's status as the "pharmacy of the world."

For UPSC aspirants, Covaxin is tested chiefly in General Studies Paper III (Science and Technology — indigenisation, R&D, intellectual property, biotechnology) and overlaps with GS-II governance/health-policy and the disaster-management dimensions of the pandemic. Typical question angles include: distinguishing Covaxin's inactivated-virus platform from Covishield's viral-vector and mRNA technologies; the roles of ICMR, NIV, Bharat Biotech and CDSCO in regulatory approval; the significance of WHO EUL for vaccine diplomacy; and the broader theme of self-reliance in critical health technologies. Prelims may pose factual matches (developer, platform type, approval date), while Mains essays on indigenous innovation and public-health response often use Covaxin as a concrete illustration. Candidates should also be able to discuss the ethical debate over emergency authorisations ahead of full efficacy disclosure.